查看购物车
  • Traditional Chinese
  • English
  • Japanese
封面
市场调查报告书
商品编码
1782000

生物相似药和生物製剂市场，按产品类型、按应用、按分销、按製造类型、按国家和地区 - 2025 年至 2032 年全球行业分析、市场规模、市场份额和预测

Biosimilar and Biologics Market, By Product Type, By Application, By Distribution, By Manufacturing Type, By Country, and By Region - Global Industry Analysis, Market Size, Market Share & Forecast from 2025-2032
出版日期: | 出版商: AnalystView Market Insights | 英文 269 Pages | 商品交期: 2-3个工作天内

价格
简介目录

报告重点

2024 年生物相似药和生物製剂市场规模价值 5,563.0944 亿美元，2025 年至 2032 年的复合年增长率为 7.81%。

生物相似药和生物製剂市场-市场动态

重磅生物製剂专利到期

生物相似药市场最重要的成长动力之一是主要生物製剂专利到期。这些生物製剂通常被称为“重磅炸弹”，每年创造数十亿美元的销售额。专利到期后，生物相似药製造商有机会开发和销售更经济实惠的替代药物。例如，阿达木单抗（Humira）是全球最畅销的生物製剂之一，用于治疗类风湿性关节炎和克隆氏症，在生物相似药进入市场之前，其年收入超过200亿美元。重磅生物製剂专利到期是生物相似药市场成长的根本驱动力。它促进了竞争，降低了药品价格，并扩大了生物疗法的可近性，最终建立了一个更永续的全球医疗保健体系。随着越来越多的生物製剂失去独占权，这一趋势将在未来十年持续下去，为生物相似药的开发和应用铺平道路。

生物相似药和生物製剂市场—关键见解

根据我们的研究分析师的分析，预计全球市场在预测期内（2025-2032 年）的年复合成长率约为 7.81%。

根据产品类型细分，预计生物製剂将在 2024 年占据最大市场份额

根据应用细分，肿瘤学是 2024 年的领先应用

根据分销细分，医院药局是 2024 年的主要分销管道

按地区划分，北美是 2024 年的主要收入来源

生物相似药和生物製剂市场細項分析：

全球生物相似药和生物製剂市场根据产品类型、应用、分销、製造类型和地区进行细分。

根据产品类型，市场分为两类：生物製剂和生物相似药。生物製剂是由生物体製成的原创复杂药物，用于治疗癌症和自体免疫疾病等疾病。生物相似药是与已核准的生物製剂高度相似、成本较低的版本，是在原厂药专利到期后开发的，具有同等的安全性和有效性。

根据应用，市场分为两类：肿瘤学、传染病、自体免疫疾病（如类风湿性关节炎、牛皮癣）、血液疾病（如贫血、血友病）、糖尿病、生长激素缺乏症、眼科疾病（如黄斑部病变）和其他（如罕见疾病、生育治疗）。癌症是全球主要死亡原因之一，由于人口老化、生活方式改变和诊断技术的进步，癌症发生率不断上升。生物製剂，尤其是单株抗体和标靶治疗，透过提供个人化、有效且比传统化疗副作用更少的解决方案，彻底改变了癌症治疗。此外，肿瘤学在生物製剂和生物相似药的研发投资、临床试验和监管批准中占很大份额，巩固了其主导地位。随着癌症病例预计将增加以及对精准医疗的关注度不断提高，肿瘤学很可能仍将是该市场中最苛刻和最有利可图的应用领域。

生物相似药和生物製剂市场—地理洞察

生物相似药和生物製剂市场在不同地理区域呈现不同的成长模式。北美，尤其是美国，凭藉其先进的医疗基础设施、强劲的研发投入以及关键製药企业的布局，在生物製剂市场占据重要份额。儘管由于监管和市场壁垒，美国生物相似药的采用最初进展缓慢，但随着修美乐（Humira）等重磅药物专利到期，这一进程正在加速。欧洲是生物相似药最成熟、最成熟的市场，这得益于其成本控制政策、欧洲药品管理局（EMA）的支持性监管框架以及医生和患者的高接受度。亚太地区是成长最快的地区，印度、中国和韩国等国家正成为主要的生物相似药製造商。庞大的患者群体、日益增长的医疗服务可及性以及不断完善的监管途径推动了这一增长。在拉丁美洲，随着各国推动医疗体系现代化并鼓励使用生物相似药以减少公共支出，市场正在稳步扩张。最后，中东和非洲代表着新兴市场，对平价生物製剂的需求不断增长，儘管其可及性和基础设施方面仍存在挑战。总体而言，儘管欧洲在生物相似药的采用方面处于领先地位，但北美和亚太地区将推动未来的市场成长。

生物相似药和生物製剂市场—竞争格局：

生物相似药和生物製剂市场的竞争格局以老牌製药巨头和新兴生物技术公司之间的激烈竞争为特征。安进、辉瑞、罗氏、诺华（山德士）、三星Bioepis、Biocon、Celltrion和迈兰（Viatris）等主要参与者占据市场主导地位，利用强大的研发能力、广泛的生产设施和全球分销网络来维持和扩大其市场份额。这些公司正在大力投资开发生物相似药，用于那些专利已过期或即将过期的高需求生物製剂。竞争不仅基于价格，还基于产品品质、监管部门的批准、专利策略以及旨在建立医生和患者信任的行销策略。此外，策略合作伙伴关係、合作以及併购也是常见的做法，旨在增强产品线组合併进入新市场。由于监管要求和市场准入存在地区差异，市场格局进一步复杂化，这影响了公司在全球范围内定位其生物相似药的方式。随着市场的发展，生物加工技术和客製化疗法的创新对于希望在这个快速成长的领域中保持竞争力的公司至关重要。

最新动态：

2025年3月，费森尤斯卡比（Fresenius Kabi）的两种地舒单抗生物相似药Conexxence和Bomyntra获得美国FDA批准，目前这两款药物分别获批用于与原参比药物Prolia和Xgeva相同的适应症。此核准为骨质疏鬆症和癌症相关骨质疏鬆症患者提供了更丰富的治疗选择，有助于提升美国市场对生物相似药的接受度。

目录

第一章：生物相似药和生物製剂市场概述

  • 研究范围
  • 市场估计年限

第二章：执行摘要

  • 市场片段
    • 生物相似药和生物製剂市场片段（按产品类型）
    • 生物相似药和生物製剂市场片段（按应用）
    • 生物相似药和生物製剂市场片段（按分布）
    • 生物相似药和生物製剂市场片段（按製造类型）
    • 生物相似药和生物製剂市场（按国家/地区）
    • 生物相似药和生物製剂市场（按地区）
  • 竞争洞察

第三章：生物相似药和生物製剂的主要市场趋势

  • 生物相似药和生物製剂市场驱动因素
    • 市场驱动因素的影响分析
  • 生物相似药和生物製剂市场限制
    • 市场限制的影响分析
  • 生物相似药和生物製剂的市场机会
  • 生物相似药和生物製剂市场未来趋势

第四章：生物相似药和生物製剂产业研究

  • PEST分析
  • 波特五力分析
  • 成长前景图
  • 规范架构分析

第五章：生物相似药和生物製剂市场：地缘政治紧张局势升级的影响

  • COVID-19 疫情的影响
  • 俄乌战争的影响
  • 中东衝突的影响

第六章：生物相似药和生物製剂市场格局

  • 2024 年生物相似药和生物製剂市场份额分析
  • 按主要製造商分類的细分数据
    • 成熟玩家分析
    • 新兴企业分析

第七章：生物相似药和生物製剂市场－依产品类型

  • 概述
    • 按产品类型分類的细分市场占有率分析
    • 生物製剂：
      • 单株抗体（mAb）
      • 疫苗
      • 重组激素（如胰岛素、人类生长激素）
      • 治疗性蛋白质（例如促红血球生成素、干扰素）
      • 血液製品
      • 基因治疗
      • 细胞疗法
    • 生物相似药：
      • 单株抗体生物相似药
      • 重组激素生物相似药（如胰岛素、生长激素）
      • 促红血球生成素生物相似药
      • 非格司亭和培非格司亭生物相似药
      • 英夫利西单抗、阿达木单抗、曲妥珠单抗生物相似药
      • 干扰素生物相似药

第 8 章：生物相似药和生物製剂市场 - 按应用

  • 概述
    • 按应用细分市场占有率分析
    • 肿瘤学
    • 传染病
    • 自体免疫疾病（例如类风湿性关节炎、牛皮癣）
    • 血液疾病（如贫血、血友病）
    • 糖尿病
    • 生长激素缺乏症
    • 眼科疾病（如黄斑部病变）
    • 其他（如罕见疾病、生育治疗）

第九章：生物相似药和生物製剂市场－依分布

  • 概述
    • 按分布细分市场占有率分析
    • 医院药房
    • 网路药局
    • 零售药局

第 10 章：生物相似药和生物製剂市场 - 按製造类型

  • 概述
    • 按製造类型分類的细分市场份额分析
    • 内部製造
    • 合约製造组织（CMO）

第 11 章：生物相似药和生物製剂市场 - 按地域划分

  • 介绍
    • 按地区分類的细分市场占有率分析
  • 北美洲
    • 概述
    • 北美生物相似药和生物製剂主要製造商
    • 北美市场规模及预测（按国家/地区）
    • 北美市场规模和预测（按产品类型）
    • 北美市场规模和预测（按应用）
    • 北美市场规模和预测（按分布）
    • 北美市场规模和预测（按技术）
    • 我们
    • 加拿大
  • 欧洲
    • 概述
    • 欧洲生物相似药和生物製剂主要製造商
    • 欧洲市场规模及预测（按国家/地区）
    • 欧洲市场规模和预测（按产品类型）
    • 欧洲市场规模和预测，按应用
    • 欧洲市场规模及预测（按分布）
    • 欧洲市场规模与预测（按技术）
    • 德国
    • 英国
    • 法国
    • 义大利
    • 西班牙
    • 荷兰
    • 瑞典
    • 俄罗斯
    • 波兰
    • 欧洲其他地区
  • 亚太地区 (APAC)
    • 概述
    • 亚太地区生物相似药和生物製剂主要製造商
    • 亚太地区市场规模及预测（依国家）
    • 亚太地区市场规模及预测（依产品类型）
    • 亚太地区市场规模及预测（按应用）
    • 亚太地区市场规模及预测（依分布）
    • 亚太地区市场规模及预测（依技术）
    • 中国
    • 印度
    • 日本
    • 韩国
    • 澳洲
    • 印尼
    • 泰国
    • 菲律宾
    • 亚太地区其他地区
  • 拉丁美洲（LATAM）
    • 概述
    • 拉丁美洲生物相似药和生物製剂主要製造商
    • 拉丁美洲市场规模及预测（按国家/地区）
    • 拉丁美洲市场规模及预测（依产品类型）
    • 拉丁美洲市场规模及预测（按应用）
    • 拉丁美洲市场规模及预测（依分布）
    • 拉丁美洲市场规模及预测（按技术）
    • 巴西
    • 墨西哥
    • 阿根廷
    • 哥伦比亚
    • 拉丁美洲其他地区
  • 中东和非洲（MEA）
    • 概述
    • 中东和非洲的生物相似药和生物製剂主要製造商
    • MEA 市场规模及预测（依国家/地区）
    • MEA 市场规模及预测（依产品类型）
    • MEA 市场规模及预测（按应用）
    • MEA 市场规模及预测（依分布）
    • MEA 市场规模及预测（依技术）
    • 沙乌地阿拉伯
    • 阿拉伯聯合大公国
    • 以色列
    • 土耳其
    • 阿尔及利亚
    • 埃及
    • MEA 其余地区

第 12 章：关键供应商分析-生物相似药和生物製剂产业

  • 竞争仪錶板
    • Competitive Benchmarking
    • Competitive Positioning
  • 公司简介
    • Amgen Inc.
    • Novartis AG (Sandoz)
    • Pfizer Inc.
    • Roche Holding AG
    • Samsung Bioepis
    • Biocon Ltd.
    • Mylan NV (Viatris)
    • Celltrion Inc.
    • Fresenius Kabi
    • Boehringer Ingelheim
    • Cipla Limited
    • Teva Pharmaceutical Industries Ltd.
    • Sandoz (a Novartis division)
    • Dr. Reddy's Laboratories
    • Intas Pharmaceuticals Ltd.
    • Zhejiang Hisun Pharmaceutical Co., Ltd.
    • LG Chem Life Sciences
    • Pfizer Inc.
    • Hetero Drugs Limited
    • Oncobiologics, Inc.
    • Others

第 13 章：360 度分析师视角

第 14 章：附录

  • 研究方法
  • 参考
  • 缩写
  • 免责声明
  • 联络我们
简介目录
Product Code: ANV5382

REPORT HIGHLIGHT

Biosimilar and Biologics Market size was valued at US$ 556,309.44 Million in 2024, expanding at a CAGR of 7.81% from 2025 to 2032.

The biosimilars and biologics market represents one of the fastest-growing sectors in the global pharmaceutical industry. Biologics are large, complex molecules or mixtures of molecules derived from living cells used in the treatment, diagnosis, or prevention of diseases. Examples include monoclonal antibodies, vaccines, and recombinant proteins. Fueled by advances in biotechnology, rising prevalence of chronic diseases, patent expirations of blockbuster biologics, and increasing healthcare costs, the market is witnessing rapid transformation.

Biosimilar and Biologics Market- Market Dynamics

Patent Expiration of Blockbuster Biologics

One of the most significant growth drivers in the biosimilars market is the expiration of patents for major biologic drugs. These biologics, often called "blockbusters", generate billions in annual sales. When their patents expire, it opens the door for biosimilar manufacturers to develop and market more affordable alternatives. For instance, Adalimumab (Humira), one of the world's top-selling biologics used to treat rheumatoid arthritis and Crohn's disease, generated over $20 billion/year in revenue before biosimilars entered the market. The expiration of patents on blockbuster biologics is a fundamental driver of growth in the biosimilar market. It enables competition, reduces drug prices, and expands access to biologic therapies-ultimately creating a more sustainable global healthcare system. This trend will continue over the next decade as more biologics lose exclusivity, paving the way for a surge in biosimilar development and adoption.

Biosimilar and Biologics Market- Key Insights

As per the analysis shared by our research analyst, the global market is estimated to grow annually at a CAGR of around 7.81% over the forecast period (2025-2032)

Based on product type segmentation, Biologics was predicted to show maximum market share in the year 2024

Based on application segmentation, Oncology was the leading application in 2024

Based on distribution segmentation, Hospital Pharmacies was the leading distribution in 2024

On the basis of region, North America was the leading revenue generator in 2024

Biosimilar and Biologics Market- Segmentation Analysis:

The Global Biosimilar and Biologics Market is segmented on the basis of Product Type, Application, Distribution, Manufacturing Type, and Region.

The market is divided into two categories based on product type: Biologics, and Biosimilars. Biologics and Biosimilars. Biologics are original, complex medicines made from living organisms, used to treat diseases like cancer and autoimmune disorders. Biosimilars are highly similar, lower-cost versions of approved biologics, developed after the original product's patent expires, offering comparable safety and effectiveness.

The market is divided into two categories based on application: Oncology, Infectious Diseases, Autoimmune Diseases (e.g., rheumatoid arthritis, psoriasis), Blood Disorders (e.g., anemia, hemophilia), Diabetes, Growth Hormone Deficiency, Ophthalmic Disorders (e.g., macular degeneration) and Others (e.g., rare diseases, fertility treatments). Cancer is one of the leading causes of death globally, with a rising incidence due to aging populations, lifestyle changes, and improved diagnostics. Biologics particularly monoclonal antibodies and targeted therapies-have revolutionized cancer treatment by offering personalized, effective solutions with fewer side effects compared to traditional chemotherapy. Additionally, oncology accounts for a large share of R&D investments, clinical trials, and regulatory approvals in both biologics and biosimilars, reinforcing its dominance. With cancer cases projected to rise and the focus on precision medicine growing, oncology will likely remain the most demanding and profitable application area in this market.

Biosimilar and Biologics Market- Geographical Insights

The biosimilar and biologics market shows varying growth patterns across different geographical regions. North America, particularly the United States, holds a major share in the biologics market due to advanced healthcare infrastructure, strong R&D investments, and the presence of key pharmaceutical players. Although biosimilar adoption was initially slow in the U.S. due to regulatory and market barriers, it is now accelerating following the expiration of patents for blockbuster drugs like Humira. Europe is the most mature and established market for biosimilars, driven by cost-containment policies, supportive regulatory frameworks by the European Medicines Agency (EMA), and high physician and patient acceptance. Asia-Pacific is the fastest-growing region, with countries like India, China, and South Korea emerging as major biosimilar manufacturers. This growth is supported by large patient populations, increasing healthcare access, and improving regulatory pathways. In Latin America, the market is expanding steadily as countries modernize their healthcare systems and encourage biosimilar use to reduce public spending. Lastly, the Middle East and Africa represent emerging markets with growing demand for affordable biologic treatments, although access and infrastructure challenges remain. Overall, while Europe leads in biosimilar adoption, North America and Asia-Pacific are set to drive future market growth.

Biosimilar and Biologics Market- Competitive Landscape:

The competitive landscape of the biosimilars and biologics market is characterized by intense rivalry among a mix of established pharmaceutical giants and emerging biotech companies. Major players like Amgen, Pfizer, Roche, Novartis (Sandoz), Samsung Bioepis, Biocon, Celltrion, and Mylan (Viatris) dominate the market, leveraging strong R&D capabilities, extensive manufacturing facilities, and global distribution networks to maintain and expand their market share. These companies are investing heavily in developing biosimilars for high-demand biologics whose patents have expired or are nearing expiration. Competition is not only based on pricing but also on product quality, regulatory approvals, patent strategies, and marketing efforts to build physician and patient trust. Additionally, strategic partnerships, collaborations, and mergers and acquisitions are common to enhance pipeline portfolios and access new markets. The landscape is further complicated by regional differences in regulatory requirements and market access, which influence how companies position their biosimilar products worldwide. As the market evolves, innovation in bioprocessing technologies and tailored therapies will be crucial for companies aiming to stay competitive in this rapidly growing sector.

Recent Developments:

In March 2025, Fresenius Kabi received U.S. FDA approval for two of their denosumab biosimilars, Conexxence and Bomyntra, which are now approved for the same indications as the original reference drugs, Prolia and Xgeva, respectively. This approval enhances treatment options for patients with osteoporosis and cancer-related bone loss, contributing to the growing acceptance of biosimilars in the U.S. market .

SCOPE OF THE REPORT

The scope of this report covers the market by its major segments, which include as follows:

GLOBAL BIOSIMILAR AND BIOLOGICS MARKET KEY PLAYERS- DETAILED COMPETITIVE INSIGHTS

  • Amgen Inc.
  • Novartis AG (Sandoz)
  • Pfizer Inc.
  • Roche Holding AG
  • Samsung Bioepis
  • Biocon Ltd.
  • Mylan N.V. (Viatris)
  • Celltrion Inc.
  • Fresenius Kabi
  • Boehringer Ingelheim
  • Cipla Limited
  • Teva Pharmaceutical Industries Ltd.
  • Sandoz (a Novartis division)
  • Dr. Reddy's Laboratories
  • Intas Pharmaceuticals Ltd.
  • Zhejiang Hisun Pharmaceutical Co., Ltd.
  • LG Chem Life Sciences
  • Pfizer Inc.
  • Hetero Drugs Limited
  • Oncobiologics, Inc.
  • Others

GLOBAL BIOSIMILAR AND BIOLOGICS MARKET, BY PRODUCT TYPE- MARKET ANALYSIS, 2019 - 2032

Biologics:

  • Monoclonal Antibodies (mAbs)
  • Vaccines
  • Recombinant Hormones (e.g., insulin, human growth hormone)
  • Therapeutic Proteins (e.g., erythropoietin, interferons)
  • Blood Products
  • Gene Therapy
  • Cell Therapy

Biosimilars:

  • Monoclonal Antibodies Biosimilars
  • Recombinant Hormones Biosimilars (e.g., insulin, growth hormone)
  • Erythropoietin Biosimilars
  • Filgrastim and Pegfilgrastim Biosimilars
  • Infliximab, Adalimumab, Trastuzumab Biosimilars
  • Interferons Biosimilars

GLOBAL BIOSIMILAR AND BIOLOGICS MARKET, BY APPLICATION- MARKET ANALYSIS, 2019 - 2032

  • Oncology
  • Infectious Diseases
  • Autoimmune Diseases (e.g., rheumatoid arthritis, psoriasis)
  • Blood Disorders (e.g., anemia, hemophilia)
  • Diabetes
  • Growth Hormone Deficiency
  • Ophthalmic Disorders (e.g., macular degeneration)
  • Others (e.g., rare diseases, fertility treatments)

GLOBAL BIOSIMILAR AND BIOLOGICS MARKET, BY DISTRIBUTION- MARKET ANALYSIS, 2019 - 2032

  • Hospital Pharmacies
  • Online Pharmacies
  • Retail Pharmacies

GLOBAL BIOSIMILAR AND BIOLOGICS MARKET, BY MANUFACTURING TYPE- MARKET ANALYSIS, 2019 - 2032

  • In-house Manufacturing
  • Contract Manufacturing Organizations (CMOs)

GLOBAL BIOSIMILAR AND BIOLOGICS MARKET, BY REGION- MARKET ANALYSIS, 2019 - 2032

  • North America
  • U.S.
  • Canada
  • Europe
  • Germany
  • UK
  • France
  • Italy
  • Spain
  • The Netherlands
  • Sweden
  • Russia
  • Poland
  • Rest of Europe
  • Asia Pacific
  • China
  • India
  • Japan
  • South Korea
  • Australia
  • Indonesia
  • Thailand
  • Philippines
  • Rest of APAC
  • Latin America
  • Brazil
  • Mexico
  • Argentina
  • Colombia
  • Rest of LATAM
  • The Middle East and Africa
  • Saudi Arabia
  • UAE
  • Israel
  • Turkey
  • Algeria
  • Egypt
  • Rest of MEA

Table of Contents

1. Biosimilar and Biologics Market Overview

  • 1.1. Study Scope
  • 1.2. Market Estimation Years

2. Executive Summary

  • 2.1. Market Snippet
    • 2.1.1. Biosimilar and Biologics Market Snippet by Product Type
    • 2.1.2. Biosimilar and Biologics Market Snippet by Application
    • 2.1.3. Biosimilar and Biologics Market Snippet by Distribution
    • 2.1.4. Biosimilar and Biologics Market Snippet by Manufacturing Type
    • 2.1.5. Biosimilar and Biologics Market Snippet by Country
    • 2.1.6. Biosimilar and Biologics Market Snippet by Region
  • 2.2. Competitive Insights

3. Biosimilar and Biologics Key Market Trends

  • 3.1. Biosimilar and Biologics Market Drivers
    • 3.1.1. Impact Analysis of Market Drivers
  • 3.2. Biosimilar and Biologics Market Restraints
    • 3.2.1. Impact Analysis of Market Restraints
  • 3.3. Biosimilar and Biologics Market Opportunities
  • 3.4. Biosimilar and Biologics Market Future Trends

4. Biosimilar and Biologics Industry Study

  • 4.1. PEST Analysis
  • 4.2. Porter's Five Forces Analysis
  • 4.3. Growth Prospect Mapping
  • 4.4. Regulatory Framework Analysis

5. Biosimilar and Biologics Market: Impact of Escalating Geopolitical Tensions

  • 5.1. Impact of COVID-19 Pandemic
  • 5.2. Impact of Russia-Ukraine War
  • 5.3. Impact of Middle East Conflicts

6. Biosimilar and Biologics Market Landscape

  • 6.1. Biosimilar and Biologics Market Share Analysis, 2024
  • 6.2. Breakdown Data, by Key Manufacturer
    • 6.2.1. Established Players' Analysis
    • 6.2.2. Emerging Players' Analysis

7. Biosimilar and Biologics Market - By Product Type

  • 7.1. Overview
    • 7.1.1. Segment Share Analysis, By Product Type, 2024 & 2032 (%)
    • 7.1.2. Biologics:
      • 7.1.2.1. Monoclonal Antibodies (mAbs)
      • 7.1.2.2. Vaccines
      • 7.1.2.3. Recombinant Hormones (e.g., insulin, human growth hormone)
      • 7.1.2.4. Therapeutic Proteins (e.g., erythropoietin, interferons)
      • 7.1.2.5. Blood Products
      • 7.1.2.6. Gene Therapy
      • 7.1.2.7. Cell Therapy
    • 7.1.3. Biosimilars:
      • 7.1.3.1. Monoclonal Antibodies Biosimilars
      • 7.1.3.2. Recombinant Hormones Biosimilars (e.g., insulin, growth hormone)
      • 7.1.3.3. Erythropoietin Biosimilars
      • 7.1.3.4. Filgrastim and Pegfilgrastim Biosimilars
      • 7.1.3.5. Infliximab, Adalimumab, Trastuzumab Biosimilars
      • 7.1.3.6. Interferons Biosimilars

8. Biosimilar and Biologics Market - By Application

  • 8.1. Overview
    • 8.1.1. Segment Share Analysis, By Application, 2024 & 2032 (%)
    • 8.1.2. Oncology
    • 8.1.3. Infectious Diseases
    • 8.1.4. Autoimmune Diseases (e.g., rheumatoid arthritis, psoriasis)
    • 8.1.5. Blood Disorders (e.g., anemia, hemophilia)
    • 8.1.6. Diabetes
    • 8.1.7. Growth Hormone Deficiency
    • 8.1.8. Ophthalmic Disorders (e.g., macular degeneration)
    • 8.1.9. Others (e.g., rare diseases, fertility treatments)

9. Biosimilar and Biologics Market - By Distribution

  • 9.1. Overview
    • 9.1.1. Segment Share Analysis, By Distribution, 2024 & 2032 (%)
    • 9.1.2. Hospital Pharmacies
    • 9.1.3. Online Pharmacies
    • 9.1.4. Retail Pharmacies

10. Biosimilar and Biologics Market - By Manufacturing Type

  • 10.1. Overview
    • 10.1.1. Segment Share Analysis, By Manufacturing Type, 2024 & 2032 (%)
    • 10.1.2. In-house Manufacturing
    • 10.1.3. Contract Manufacturing Organizations (CMOs)

11. Biosimilar and Biologics Market- By Geography

  • 11.1. Introduction
    • 11.1.1. Segment Share Analysis, By Geography, 2024 & 2032 (%)
  • 11.2. North America
    • 11.2.1. Overview
    • 11.2.2. Biosimilar and Biologics Key Manufacturers in North America
    • 11.2.3. North America Market Size and Forecast, By Country, 2019 - 2032 (US$ Million)
    • 11.2.4. North America Market Size and Forecast, By Product Type, 2019 - 2032 (US$ Million)
    • 11.2.5. North America Market Size and Forecast, By Application, 2019 - 2032 (US$ Million)
    • 11.2.6. North America Market Size and Forecast, By Distribution, 2019 - 2032 (US$ Million)
    • 11.2.7. North America Market Size and Forecast, By Technology, 2019 - 2032 (US$ Million)
    • 11.2.8. U.S.
      • 11.2.8.1. Overview
      • 11.2.8.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.2.8.3. U.S. Market Size and Forecast, By Product Type, 2019 - 2032 (US$ Million)
      • 11.2.8.4. U.S. Market Size and Forecast, By Application, 2019 - 2032 (US$ Million)
      • 11.2.8.5. U.S. Market Size and Forecast, By Distribution, 2019 - 2032 (US$ Million)
      • 11.2.8.6. U.S. Market Size and Forecast, By Technology, 2019 - 2032 (US$ Million)
    • 11.2.9. Canada
      • 11.2.9.1. Overview
      • 11.2.9.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.2.9.3. Canada Market Size and Forecast, By Product Type, 2019 - 2032 (US$ Million)
      • 11.2.9.4. Canada Market Size and Forecast, By Application, 2019 - 2032 (US$ Million)
      • 11.2.9.5. Canada Market Size and Forecast, By Distribution, 2019 - 2032 (US$ Million)
      • 11.2.9.6. Canada Market Size and Forecast, By Technology, 2019 - 2032 (US$ Million)
  • 11.3. Europe
    • 11.3.1. Overview
    • 11.3.2. Biosimilar and Biologics Key Manufacturers in Europe
    • 11.3.3. Europe Market Size and Forecast, By Country, 2019 - 2032 (US$ Million)
    • 11.3.4. Europe Market Size and Forecast, By Product Type, 2019 - 2032 (US$ Million)
    • 11.3.5. Europe Market Size and Forecast, By Application, 2019 - 2032 (US$ Million)
    • 11.3.6. Europe Market Size and Forecast, By Distribution, 2019 - 2032 (US$ Million)
    • 11.3.7. Europe Market Size and Forecast, By Technology, 2019 - 2032 (US$ Million)
    • 11.3.8. Germany
      • 11.3.8.1. Overview
      • 11.3.8.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.3.8.3. Germany Market Size and Forecast, By Product Type, 2019 - 2032 (US$ Million)
      • 11.3.8.4. Germany Market Size and Forecast, By Application, 2019 - 2032 (US$ Million)
      • 11.3.8.5. Germany Market Size and Forecast, By Distribution, 2019 - 2032 (US$ Million)
      • 11.3.8.6. Germany Market Size and Forecast, By Technology, 2019 - 2032 (US$ Million)
    • 11.3.9. UK
      • 11.3.9.1. Overview
      • 11.3.9.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.3.9.3. UK Market Size and Forecast, By Product Type, 2019 - 2032 (US$ Million)
      • 11.3.9.4. UK Market Size and Forecast, By Application, 2019 - 2032 (US$ Million)
      • 11.3.9.5. UK Market Size and Forecast, By Distribution, 2019 - 2032 (US$ Million)
      • 11.3.9.6. UK Market Size and Forecast, By Technology, 2019 - 2032 (US$ Million)
    • 11.3.10. France
      • 11.3.10.1. Overview
      • 11.3.10.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.3.10.3. France Market Size and Forecast, By Product Type, 2019 - 2032 (US$ Million)
      • 11.3.10.4. France Market Size and Forecast, By Application, 2019 - 2032 (US$ Million)
      • 11.3.10.5. France Market Size and Forecast, By Distribution, 2019 - 2032 (US$ Million)
      • 11.3.10.6. France Market Size and Forecast, By Technology, 2019 - 2032 (US$ Million)
    • 11.3.11. Italy
      • 11.3.11.1. Overview
      • 11.3.11.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.3.11.3. Italy Market Size and Forecast, By Product Type, 2019 - 2032 (US$ Million)
      • 11.3.11.4. Italy Market Size and Forecast, By Application, 2019 - 2032 (US$ Million)
      • 11.3.11.5. Italy Market Size and Forecast, By Distribution, 2019 - 2032 (US$ Million)
      • 11.3.11.6. Italy Market Size and Forecast, By Technology, 2019 - 2032 (US$ Million)
    • 11.3.12. Spain
      • 11.3.12.1. Overview
      • 11.3.12.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.3.12.3. Spain Market Size and Forecast, By Product Type, 2019 - 2032 (US$ Million)
      • 11.3.12.4. Spain Market Size and Forecast, By Application, 2019 - 2032 (US$ Million)
      • 11.3.12.5. Spain Market Size and Forecast, By Distribution, 2019 - 2032 (US$ Million)
      • 11.3.12.6. Spain Market Size and Forecast, By Technology, 2019 - 2032 (US$ Million)
    • 11.3.13. The Netherlands
      • 11.3.13.1. Overview
      • 11.3.13.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.3.13.3. The Netherlands Market Size and Forecast, By Product Type, 2019 - 2032 (US$ Million)
      • 11.3.13.4. The Netherlands Market Size and Forecast, By Application, 2019 - 2032 (US$ Million)
      • 11.3.13.5. The Netherlands Market Size and Forecast, By Distribution, 2019 - 2032 (US$ Million)
      • 11.3.13.6. The Netherlands Market Size and Forecast, By Technology, 2019 - 2032 (US$ Million)
    • 11.3.14. Sweden
      • 11.3.14.1. Overview
      • 11.3.14.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.3.14.3. Sweden Market Size and Forecast, By Product Type, 2019 - 2032 (US$ Million)
      • 11.3.14.4. Sweden Market Size and Forecast, By Application, 2019 - 2032 (US$ Million)
      • 11.3.14.5. Sweden Market Size and Forecast, By Distribution, 2019 - 2032 (US$ Million)
      • 11.3.14.6. Sweden Market Size and Forecast, By Technology, 2019 - 2032 (US$ Million)
    • 11.3.15. Russia
      • 11.3.15.1. Overview
      • 11.3.15.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.3.15.3. Russia Market Size and Forecast, By Product Type, 2019 - 2032 (US$ Million)
      • 11.3.15.4. Russia Market Size and Forecast, By Application, 2019 - 2032 (US$ Million)
      • 11.3.15.5. Russia Market Size and Forecast, By Distribution, 2019 - 2032 (US$ Million)
      • 11.3.15.6. Russia Market Size and Forecast, By Technology, 2019 - 2032 (US$ Million)
    • 11.3.16. Poland
      • 11.3.16.1. Overview
      • 11.3.16.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.3.16.3. Poland Market Size and Forecast, By Product Type, 2019 - 2032 (US$ Million)
      • 11.3.16.4. Poland Market Size and Forecast, By Application, 2019 - 2032 (US$ Million)
      • 11.3.16.5. Poland Market Size and Forecast, By Distribution, 2019 - 2032 (US$ Million)
      • 11.3.16.6. Poland Market Size and Forecast, By Technology, 2019 - 2032 (US$ Million)
    • 11.3.17. Rest of Europe
      • 11.3.17.1. Overview
      • 11.3.17.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.3.17.3. Rest of the Europe Market Size and Forecast, By Product Type, 2019 - 2032 (US$ Million)
      • 11.3.17.4. Rest of the Europe Market Size and Forecast, By Application, 2019 - 2032 (US$ Million)
      • 11.3.17.5. Rest of the Europe Market Size and Forecast, By Distribution, 2019 - 2032 (US$ Million)
      • 11.3.17.6. Rest of the Europe Market Size and Forecast, By Technology, 2019 - 2032 (US$ Million)
  • 11.4. Asia Pacific (APAC)
    • 11.4.1. Overview
    • 11.4.2. Biosimilar and Biologics Key Manufacturers in Asia Pacific
    • 11.4.3. APAC Market Size and Forecast, By Country, 2019 - 2032 (US$ Million)
    • 11.4.4. APAC Market Size and Forecast, By Product Type, 2019 - 2032 (US$ Million)
    • 11.4.5. APAC Market Size and Forecast, By Application, 2019 - 2032 (US$ Million)
    • 11.4.6. APAC Market Size and Forecast, By Distribution, 2019 - 2032 (US$ Million)
    • 11.4.7. APAC Market Size and Forecast, By Technology, 2019 - 2032 (US$ Million)
    • 11.4.8. China
      • 11.4.8.1. Overview
      • 11.4.8.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.4.8.3. China Market Size and Forecast, By Product Type, 2019 - 2032 (US$ Million)
      • 11.4.8.4. China Market Size and Forecast, By Application, 2019 - 2032 (US$ Million)
      • 11.4.8.5. China Market Size and Forecast, By Distribution, 2019 - 2032 (US$ Million)
      • 11.4.8.6. China Market Size and Forecast, By Technology, 2019 - 2032 (US$ Million)
    • 11.4.9. India
      • 11.4.9.1. Overview
      • 11.4.9.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.4.9.3. India Market Size and Forecast, By Product Type, 2019 - 2032 (US$ Million)
      • 11.4.9.4. India Market Size and Forecast, By Application, 2019 - 2032 (US$ Million)
      • 11.4.9.5. India Market Size and Forecast, By Distribution, 2019 - 2032 (US$ Million)
      • 11.4.9.6. India Market Size and Forecast, By Technology, 2019 - 2032 (US$ Million)
    • 11.4.10. Japan
      • 11.4.10.1. Overview
      • 11.4.10.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.4.10.3. Japan Market Size and Forecast, By Product Type, 2019 - 2032 (US$ Million)
      • 11.4.10.4. Japan Market Size and Forecast, By Application, 2019 - 2032 (US$ Million)
      • 11.4.10.5. Japan Market Size and Forecast, By Distribution, 2019 - 2032 (US$ Million)
      • 11.4.10.6. Japan Market Size and Forecast, By Technology, 2019 - 2032 (US$ Million)
    • 11.4.11. South Korea
      • 11.4.11.1. Overview
      • 11.4.11.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.4.11.3. South Korea Market Size and Forecast, By Product Type, 2019 - 2032 (US$ Million)
      • 11.4.11.4. South Korea Market Size and Forecast, By Application, 2019 - 2032 (US$ Million)
      • 11.4.11.5. South Korea Market Size and Forecast, By Distribution, 2019 - 2032 (US$ Million)
      • 11.4.11.6. South Korea Market Size and Forecast, By Technology, 2019 - 2032 (US$ Million)
    • 11.4.12. Australia
      • 11.4.12.1. Overview
      • 11.4.12.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.4.12.3. Australia Market Size and Forecast, By Product Type, 2019 - 2032 (US$ Million)
      • 11.4.12.4. Australia Market Size and Forecast, By Application, 2019 - 2032 (US$ Million)
      • 11.4.12.5. Australia Market Size and Forecast, By Distribution, 2019 - 2032 (US$ Million)
      • 11.4.12.6. Australia Market Size and Forecast, By Technology, 2019 - 2032 (US$ Million)
    • 11.4.13. Indonesia
      • 11.4.13.1. Overview
      • 11.4.13.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.4.13.3. Indonesia Market Size and Forecast, By Product Type, 2019 - 2032 (US$ Million)
      • 11.4.13.4. Indonesia Market Size and Forecast, By Application, 2019 - 2032 (US$ Million)
      • 11.4.13.5. Indonesia Market Size and Forecast, By Distribution, 2019 - 2032 (US$ Million)
      • 11.4.13.6. Indonesia Market Size and Forecast, By Technology, 2019 - 2032 (US$ Million)
    • 11.4.14. Thailand
      • 11.4.14.1. Overview
      • 11.4.14.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.4.14.3. Thailand Market Size and Forecast, By Product Type, 2019 - 2032 (US$ Million)
      • 11.4.14.4. Thailand Market Size and Forecast, By Application, 2019 - 2032 (US$ Million)
      • 11.4.14.5. Thailand Market Size and Forecast, By Distribution, 2019 - 2032 (US$ Million)
      • 11.4.14.6. Thailand Market Size and Forecast, By Technology, 2019 - 2032 (US$ Million)
    • 11.4.15. Philippines
      • 11.4.15.1. Overview
      • 11.4.15.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.4.15.3. Philippines Market Size and Forecast, By Product Type, 2019 - 2032 (US$ Million)
      • 11.4.15.4. Philippines Market Size and Forecast, By Application, 2019 - 2032 (US$ Million)
      • 11.4.15.5. Philippines Market Size and Forecast, By Distribution, 2019 - 2032 (US$ Million)
      • 11.4.15.6. Philippines Market Size and Forecast, By Technology, 2019 - 2032 (US$ Million)
    • 11.4.16. Rest of APAC
      • 11.4.16.1. Overview
      • 11.4.16.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.4.16.3. Rest of APAC Market Size and Forecast, By Product Type, 2019 - 2032 (US$ Million)
      • 11.4.16.4. Rest of APAC Market Size and Forecast, By Application, 2019 - 2032 (US$ Million)
      • 11.4.16.5. Rest of APAC Market Size and Forecast, By Distribution, 2019 - 2032 (US$ Million)
      • 11.4.16.6. Rest of APAC Market Size and Forecast, By Technology, 2019 - 2032 (US$ Million)
  • 11.5. Latin America (LATAM)
    • 11.5.1. Overview
    • 11.5.2. Biosimilar and Biologics Key Manufacturers in Latin America
    • 11.5.3. LATAM Market Size and Forecast, By Country, 2019 - 2032 (US$ Million)
    • 11.5.4. LATAM Market Size and Forecast, By Product Type, 2019 - 2032 (US$ Million)
    • 11.5.5. LATAM Market Size and Forecast, By Application, 2019 - 2032 (US$ Million)
    • 11.5.6. LATAM Market Size and Forecast, By Distribution, 2019 - 2032 (US$ Million)
    • 11.5.7. LATAM Market Size and Forecast, By Technology, 2019 - 2032 (US$ Million)
    • 11.5.8. Brazil
      • 11.5.8.1. Overview
      • 11.5.8.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.5.8.3. Brazil Market Size and Forecast, By Product Type, 2019 - 2032 (US$ Million)
      • 11.5.8.4. Brazil Market Size and Forecast, By Application, 2019 - 2032 (US$ Million)
      • 11.5.8.5. Brazil Market Size and Forecast, By Distribution, 2019 - 2032 (US$ Million)
      • 11.5.8.6. Brazil Market Size and Forecast, By Technology, 2019 - 2032 (US$ Million)
    • 11.5.9. Mexico
      • 11.5.9.1. Overview
      • 11.5.9.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.5.9.3. Mexico Market Size and Forecast, By Product Type, 2019 - 2032 (US$ Million)
      • 11.5.9.4. Mexico Market Size and Forecast, By Application, 2019 - 2032 (US$ Million)
      • 11.5.9.5. Mexico Market Size and Forecast, By Distribution, 2019 - 2032 (US$ Million)
      • 11.5.9.6. Mexico Market Size and Forecast, By Technology, 2019 - 2032 (US$ Million)
    • 11.5.10. Argentina
      • 11.5.10.1. Overview
      • 11.5.10.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.5.10.3. Argentina Market Size and Forecast, By Product Type, 2019 - 2032 (US$ Million)
      • 11.5.10.4. Argentina Market Size and Forecast, By Application, 2019 - 2032 (US$ Million)
      • 11.5.10.5. Argentina Market Size and Forecast, By Distribution, 2019 - 2032 (US$ Million)
      • 11.5.10.6. Argentina Market Size and Forecast, By Technology, 2019 - 2032 (US$ Million)
    • 11.5.11. Colombia
      • 11.5.11.1. Overview
      • 11.5.11.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.5.11.3. Colombia Market Size and Forecast, By Product Type, 2019 - 2032 (US$ Million)
      • 11.5.11.4. Colombia Market Size and Forecast, By Application, 2019 - 2032 (US$ Million)
      • 11.5.11.5. Colombia Market Size and Forecast, By Distribution, 2019 - 2032 (US$ Million)
      • 11.5.11.6. Colombia Market Size and Forecast, By Technology, 2019 - 2032 (US$ Million)
    • 11.5.12. Rest of LATAM
      • 11.5.12.1. Overview
      • 11.5.12.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.5.12.3. Rest of LATAM Market Size and Forecast, By Product Type, 2019 - 2032 (US$ Million)
      • 11.5.12.4. Rest of LATAM Market Size and Forecast, By Application, 2019 - 2032 (US$ Million)
      • 11.5.12.5. Rest of LATAM Market Size and Forecast, By Distribution, 2019 - 2032 (US$ Million)
      • 11.5.12.6. Rest of LATAM Market Size and Forecast, By Technology, 2019 - 2032 (US$ Million)
  • 11.6. Middle East and Africa (MEA)
    • 11.6.1. Overview
    • 11.6.2. Biosimilar and Biologics Key Manufacturers in Middle East and Africa
    • 11.6.3. MEA Market Size and Forecast, By Country, 2019 - 2032 (US$ Million)
    • 11.6.4. MEA Market Size and Forecast, By Product Type, 2019 - 2032 (US$ Million)
    • 11.6.5. MEA Market Size and Forecast, By Application, 2019 - 2032 (US$ Million)
    • 11.6.6. MEA Market Size and Forecast, By Distribution, 2019 - 2032 (US$ Million)
    • 11.6.7. MEA Market Size and Forecast, By Technology, 2019 - 2032 (US$ Million)
    • 11.6.8. Saudi Arabia
      • 11.6.8.1. Overview
      • 11.6.8.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.6.8.3. Saudi Arabia Market Size and Forecast, By Product Type, 2019 - 2032 (US$ Million)
      • 11.6.8.4. Saudi Arabia Market Size and Forecast, By Application, 2019 - 2032 (US$ Million)
      • 11.6.8.5. Saudi Arabia Market Size and Forecast, By Distribution, 2019 - 2032 (US$ Million)
      • 11.6.8.6. Saudi Arabia Market Size and Forecast, By Technology, 2019 - 2032 (US$ Million)
    • 11.6.9. United Arab Emirates
      • 11.6.9.1. Overview
      • 11.6.9.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.6.9.3. United Arab Emirates Market Size and Forecast, By Product Type, 2019 - 2032 (US$ Million)
      • 11.6.9.4. United Arab Emirates Market Size and Forecast, By Application, 2019 - 2032 (US$ Million)
      • 11.6.9.5. United Arab Emirates Market Size and Forecast, By Distribution, 2019 - 2032 (US$ Million)
      • 11.6.9.6. United Arab Emirates Market Size and Forecast, By Technology, 2019 - 2032 (US$ Million)
    • 11.6.10. Israel
      • 11.6.10.1. Overview
      • 11.6.10.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.6.10.3. Israel Market Size and Forecast, By Product Type, 2019 - 2032 (US$ Million)
      • 11.6.10.4. Israel Market Size and Forecast, By Application, 2019 - 2032 (US$ Million)
      • 11.6.10.5. Israel Market Size and Forecast, By Distribution, 2019 - 2032 (US$ Million)
      • 11.6.10.6. Israel Market Size and Forecast, By Technology, 2019 - 2032 (US$ Million)
    • 11.6.11. Turkey
      • 11.6.11.1. Overview
      • 11.6.11.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.6.11.3. Turkey Market Size and Forecast, By Product Type, 2019 - 2032 (US$ Million)
      • 11.6.11.4. Turkey Market Size and Forecast, By Application, 2019 - 2032 (US$ Million)
      • 11.6.11.5. Turkey Market Size and Forecast, By Distribution, 2019 - 2032 (US$ Million)
      • 11.6.11.6. Turkey Market Size and Forecast, By Technology, 2019 - 2032 (US$ Million)
    • 11.6.12. Algeria
      • 11.6.12.1. Overview
      • 11.6.12.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.6.12.3. Algeria Market Size and Forecast, By Product Type, 2019 - 2032 (US$ Million)
      • 11.6.12.4. Algeria Market Size and Forecast, By Application, 2019 - 2032 (US$ Million)
      • 11.6.12.5. Algeria Market Size and Forecast, By Distribution, 2019 - 2032 (US$ Million)
      • 11.6.12.6. Algeria Market Size and Forecast, By Technology, 2019 - 2032 (US$ Million)
    • 11.6.13. Egypt
      • 11.6.13.1. Overview
      • 11.6.13.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.6.13.3. Egypt Market Size and Forecast, By Product Type, 2019 - 2032 (US$ Million)
      • 11.6.13.4. Egypt Market Size and Forecast, By Application, 2019 - 2032 (US$ Million)
      • 11.6.13.5. Egypt Market Size and Forecast, By Distribution, 2019 - 2032 (US$ Million)
      • 11.6.13.6. Egypt Market Size and Forecast, By Technology, 2019 - 2032 (US$ Million)
    • 11.6.14. Rest of MEA
      • 11.6.14.1. Overview
      • 11.6.14.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.6.14.3. Rest of MEA Market Size and Forecast, By Product Type, 2019 - 2032 (US$ Million)
      • 11.6.14.4. Rest of MEA Market Size and Forecast, By Application, 2019 - 2032 (US$ Million)
      • 11.6.14.5. Rest of MEA Market Size and Forecast, By Distribution, 2019 - 2032 (US$ Million)
      • 11.6.14.6. Rest of MEA Market Size and Forecast, By Technology, 2019 - 2032 (US$ Million)

12. Key Vendor Analysis- Biosimilar and Biologics Industry

  • 12.1. Competitive Dashboard
    • 12.1.1. Competitive Benchmarking
    • 12.1.2. Competitive Positioning
  • 12.2. Company Profiles
    • 12.2.1. Amgen Inc.
    • 12.2.2. Novartis AG (Sandoz)
    • 12.2.3. Pfizer Inc.
    • 12.2.4. Roche Holding AG
    • 12.2.5. Samsung Bioepis
    • 12.2.6. Biocon Ltd.
    • 12.2.7. Mylan N.V. (Viatris)
    • 12.2.8. Celltrion Inc.
    • 12.2.9. Fresenius Kabi
    • 12.2.10. Boehringer Ingelheim
    • 12.2.11. Cipla Limited
    • 12.2.12. Teva Pharmaceutical Industries Ltd.
    • 12.2.13. Sandoz (a Novartis division)
    • 12.2.14. Dr. Reddy's Laboratories
    • 12.2.15. Intas Pharmaceuticals Ltd.
    • 12.2.16. Zhejiang Hisun Pharmaceutical Co., Ltd.
    • 12.2.17. LG Chem Life Sciences
    • 12.2.18. Pfizer Inc.
    • 12.2.19. Hetero Drugs Limited
    • 12.2.20. Oncobiologics, Inc.
    • 12.2.21. Others

13. 360 Degree AnalystView

14. Appendix

  • 14.1. Research Methodology
  • 14.2. References
  • 14.3. Abbreviations
  • 14.4. Disclaimer
  • 14.5. Contact Us